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http://respiratory-research.com/content/15/1/40RESEARCH Open AccessFrequent utilization of the emergency
department for acute exacerbation of chronic
obstructive pulmonary disease
Kohei Hasegawa1,2*, Yusuke Tsugawa3, Chu-Lin Tsai1,2, David FM Brown1,2 and Carlos A Camargo Jr1,2Abstract
Background: Little is known about patients who frequently visit the emergency department (ED) for acute
exacerbation of chronic obstructive pulmonary disease (AECOPD). We aimed to quantify the proportion and
characteristics of patients with frequent ED visits for AECOPD and associated healthcare utilization.
Methods: We conducted a retrospective cohort study of adults aged ≥40 years with at least one ED visit for
AECOPD between 2010 and 2011, derived from population-based all-payer data of State ED and Inpatient Databases
for two large and diverse states: California and Florida. Outcome measures were frequency of ED visits for AECOPD,
30-day ED revisits, subsequent hospitalizations, near-fatal events (AECOPD involving mechanical ventilation), and
charges for both ED and inpatient services (available only for Florida) during the year after the first ED visit.
Results: The analytic cohort comprised 98,280 unique patients with 154,736 ED visits for AECOPD. During the
1-year period, 29.4% (95% CI, 29.1%-29.7%) of the patients had two or more (frequent) visits, accounting for 55.2%
(95% CI, 54.9%-55.4%) of all ED visits for AECOPD. In the multivariable model, significant predictors of frequent ED
visits were age 55–74 years (vs. 40–54 years), male sex, non-Hispanic white or black race, Medicaid insurance
(vs. private), and lower median household income (all P < 0.001). At the visit-level, 12.3% of ED visits for AECOPD
were 30-day revisit events (95% CI, 12.1%-12.4%). Additionally, 62.8% of ED visits for AECOPD (95% CI, 62.6%-63.0%)
resulted in a hospitalization; patients with frequent ED visits comprised 55.5% (95% CI, 55.2%-55.8%) of all
hospitalizations. Furthermore, 7.3% (95% CI, 7.3%-7.5%) of ED visits for AECOPD led to a near-fatal event; patients
with frequent ED visits accounted for 64.4% (95% CI, 63.5%-65.3%) of all near-fatal events. Total charges for
AECOPD were $1.94 billion (95% CI, $1.90-1.97 billion) in Florida; patients with frequent ED visits accounted for
$1.07 billion (95% CI, $1.04-1.09 billion).
Conclusions: In this large cohort study, we found that 29% had frequent ED visits for AECOPD and that lower
socioeconomic status was significantly associated with a higher frequency of ED visits. Individuals with frequent
ED visits for AECOPD accounted for a substantial amount of healthcare utilization and financial burden.
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Chronic obstructive pulmonary disease (COPD) is a
serious public health problem in the US. Acute exa-
cerbations of COPD (AECOPD) were responsible for
approximately 1.5 million emergency department (ED)
visits and 700,000 hospitalizations in 2010 [1]. Further-
more, acute exacerbations accelerate decline in lung
function, reduce patient’s quality of life, and increase
health care use [2-4]. Indeed, exacerbation management
was estimated to account for up to 70% of total direct
costs of COPD management [5,6].
In this context, the US government recently identi-
fied reducing ED visits for AECOPD as a national ob-
jective in Healthy People 2020 [7]. To develop and
implement preventive strategies effectively, identifying
patients at risk for future exacerbations is critical. Prior
studies have identified risk factors associated with fre-
quent exacerbations (2 or more exacerbations in a
year), such as a history of previous exacerbations, dis-
ease severity, poor disease-specific health status, gas-
troesophageal reflex, and non-private insurance status
[8-11]. However, these studies were conducted within
limited populations (e.g., patients in urban academic
centers, and population in one state), thereby limiting
generalizability of their results. Despite a substantial
burden of COPD-related ED visits in an already
stressed healthcare system, there have been no large
cohort studies to characterize this high-risk patient
population in the US.
To address these knowledge gaps, using large all-
payer databases from two geographically dispersed
states, we sought to quantify the proportion and char-
acteristics of patients with frequent ED visits for
AECOPD and associated healthcare burden, including
rates of 30-day ED revisit, hospitalizations, near-fatal
events, and hospital charges. A better understanding of
these important issues in ED patients with AECOPD
may inform potential strategies to improve their COPD
management and reduce healthcare spending.
Methods
Study design and setting
We conducted a retrospective cohort study using data
from the Healthcare Cost and Utilization Project (HCUP)
State Emergency Department Databases (SEDD) and
State Inpatient Databases (SID). The SEDD includes all
treat-and-release and transfer ED visits from short-
term, acute-care, nonfederal, community hospitals in
participating states. The SID includes all inpatient dis-
charges from short-term, acute-care, nonfederal, ge-
neral, and other specialty hospitals in participating
states, including those admitted from the ED. Taken
together, we identified all ED visits regardless of dis-
position and contained information on short-termoutcomes for patients admitted through the ED. Add-
itional details of the SEDD and SID can be found else-
where [12,13].
In this study, we used the data from California and
Florida SEDD and SID in 2010 and 2011. These two
states were selected for their geographic distribution,
high data quality, and mainly because their databases
included unique encrypted patient-level identifiers that
enable follow-up of specific patients across years. The
institutional review board of our hospital waived review
of this study.Study population
We identified all adults aged 40 years or older with
at least one ED visit for AECOPD in 2010, by using
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) code for: 1) chronic
bronchitis (491.xx), emphysema (492.xx), or chronic air-
way obstruction (496.xx) in the primary diagnosis field;
or 2) acute respiratory failure (518.81, 518.82, or 518.84)
listed in the primary diagnosis field and COPD listed as
the secondary diagnosis (491.xx, 492.xx, or 496.xx). To
minimize the potential misclassification of acute bron-
chitis as COPD, we did not include bronchitis not speci-
fied (490.xx). Likewise, we excluded patients younger
than 40 years because they are less likely to have COPD
[5]. We also excluded out-of-state residents, and patients
who died at the first ED visit or hospitalization during
the study period.Covariates
The databases contain information on patient charac-
teristics, including demographics (age, sex, and race/
ethnicity), primary insurance type, household income,
urban–rural status, ICD-9-CM diagnosis, and patient
comorbidities. The SEDD database also includes ED
disposition. The patient characteristics at the first visit
were used for the primary analysis. Primary insurance
types were categorized into Medicaid, Medicare, private
sources, self-pay, and other. Quartile classifications of
estimated median household income of residents in the
patient’s ZIP Code were examined. These values were
derived from the annual ZIP Code-demographic data
and included in the SEDD and SID databases. Because
these estimate are updated annually, the values ranges
for the categories vary by year [12,13]. Urban–rural sta-
tus of the patient residence was defined according to
the National Center for Health Statistics [14]. To adjust
for potential confounding by patient-mix, 29 Elixhauser
comorbidity measures were derived based on the ICD-
9-CM codes using the Agency for Healthcare Research
and Quality (AHRQ) Comorbidity Software [15]. This
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extensively [16].
Outcome measures
The primary outcome measure was the frequency of ED
visits for AECOPD in a given year for each patient. The
patient’s first ED visit in 2010 was identified as the index
ED visit. Each patient was then followed for 365 days
after the index visit; then, the total number of ED visits
for each patient was summated during the follow-up
period, including the index visit.
Other outcome measures of interest were 30-day ED
revisits, hospitalizations, near-fatal events, and charges
for both ED and inpatient services. Thirty-day ED
revisit was defined as an ED visit for AECOPD within
30 days of the previous ED or hospital discharge.
Hospitalization was defined as a hospital admission
for AECOPD from ED during the year after the index
visit. Near-fatal event was defined as an ED visit or
hospitalization for AECOPD involving noninvasive or
invasive mechanical ventilation [17]; the use of me-
chanical ventilation was identified using the HCUP
Clinical Classifications Software code 216. Charges re-
flect the total facility fees aggregated for a given indi-
vidual; they are not available in the California datasets.
All charges were converted to 2011 US dollars using
the medical component of the Consumer Price Index
[18].
Statistical analysis
For the purpose of this analysis, we categorized patients
into three ED utilization groups according to the distri-
bution of COPD-related ED visits and previous literature
[8]: one ED visit (i.e., index visit only), two ED visits,
and three or more ED visits within one year. First, we
tested for unadjusted associations between patient-level
variables and the frequency of ED visits for AECOPD
using chi-square test or Kruskal-Wallis test, as appropri-
ate. The patient-level covariates at the first visit were
used for the analysis. Then, we fit multinomial logistic
regression models to examine associations between
patient-level variables and frequency of ED visits, with
one ED visit group as the reference, adjusting for
patient-mix using Elixhauser comorbidity measures.
Additionally, we calculated the rate of 30-day ED re-
visits, hospitalizations, and near-fatal events according
to the ED visit utilization. The rates were defined as the
total number of respective outcomes within a year of the
index ED visit divided by the total number of ED visits
for AECOPD. Then, we examined associations between
the frequency of ED visits and these rates. We also per-
formed linear regression at the patient-level to examine
a linear association between the frequency of ED visits
and charges.In sensitivity analyses, to assess the consistency of
associations between the frequency of ED visits and each
outcome, we stratified the analysis by state, and included
data from Nebraska. Data from Nebraska was not used
for the primary analysis as they did not include race/
ethnicity. Additionally, to further investigate predictors
of a higher frequency of ED visits, a negative binomial
regression model with quasi-likelihood estimation was
used [19]. This model has advantages that there is
no need to define an arbitrary cutoff point and that
this model appropriately accounts for statistical over-
dispersion [20,21]. All analyses were performed with
SAS version 9.3 (SAS Institute, Cary, NC) and re-
sults were presented with 95% confidence interval
(CI), when appropriate. A two-sided P value <0.05
was considered statistically significant.
Results
All ED visits for AECOPD made by patients aged
40 years or older in 2010 and 2011 (n = 294,678) were
identified in the California and Florida databases. From
this population, we sequentially excluded ED visits
occurred >365 days after the index visit (n = 23,485),
those made by patients who had no ED visits in 2010
(n = 104,510), and those without a valid encrypted pa-
tient identifier (n = 6,583). We also excluded ED visits
made by patients with out-of-state residence (n = 4,331)
or who died at the index ED visit (n = 1033). After these
exclusions, the analytic cohort comprised 98,280 unique
patients with 154,736 ED visits for AECOPD.
ED visits for AECOPD
Among this analytic cohort, 69,398 patients (70.6%; 95%
CI, 70.3%-70.9%) reported one ED visit during the 1-year
study period, while 28,882 patients (29.4%; 95% CI, 29.1%-
29.7%) had two or more (frequent) visits. Figure 1 demon-
strates the number of patients and ED visits for AECOPD
during the study period by ED visit frequency. Patients
with frequent visits accounted for 55.2% (95% CI, 54.9%-
55.4%) of all ED visits for AECOPD.
In the sensitivity analysis, the distribution of ED visit
frequency was similar across California and Florida
(Figure 2), with the comparable findings in Nebraska.
For example, 29.7% of patients in California had fre-
quent ED visits and accounted for 55.9% (95% CI,
55.5%-56,2%) of all ED visits; 29.1% patients in Florida
had frequent visits and accounted for 54.5% (95% CI,
54.1%-54.8%) of all ED visits; 29.6% patients in Nebraska
had frequent ED visits and accounted for 54.0% (95% CI,
52.5%-55.5%) of all ED visits.
Patient characteristics
Patient demographics, socioeconomic factors, and co-
morbidities differed across the ED visit frequency groups
1 2 3 4 5 6 7 8 9 10+
Number of COPD patients 69,465 17,005 5,974 2,629 1,287 713 422 254 183 415
Number of COPD ED visits 69,465 34,010 17,922 10,516 6,435 4,278 2,954 2,032 1,647 5,544
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Figure 1 Number of patients and emergency department (ED) visits for acute exacerbation of chronic obstructive pulmonary disease
(AECOPD), according to ED visit frequency.
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tients with a higher frequency of ED visits were more
likely to be age 55–74 years, male sex, and non-Hispanic
black race. Similarly, several markers of socioeconomic
status, such as Medicaid insurance and lower median
household income, were associated with a higher fre-
quency of ED visits.
In a multinomial logistic regression model (Table 2),
these patient characteristics remained significant as
independent predictors of a higher frequency of ED
visits across the frequency groups. For example,
non-Hispanic white race (OR, 1.32; 95% CI, 1.23-1.41),1 2 3 4 5
California 33,741 16,594 8,892 5,144 3,32
Florida 35,657 17,416 9,030 5,372 3,11
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Figure 2 Number of emergency department (ED) visits for acute exac
according to ED visit frequency, stratified by state.non-Hispanic black race (OR, 1.59; 95% CI, 1.45-1.73),
Medicaid insurance (OR, 2.92; 95% CI, 2.66-3.20), and
lowest quartile for household income (OR, 1.29; 95%
CI, 1.21-1.38) were independently associated with
three or more ED visits within one year. In addition,
certain comorbidities such as congestive heart failure,
pulmonary circulation disorders, depression, and psych-
oses were associated with a higher frequency of ED
visits. In the sensitivity analyses, these associations
remained statistically significant with stratification by
state and the use of negative binomial regression model
(Tables 3 and 4).6 7 8 9 10+
5 2,148 1,421 1,000 900 3,270
0 2,130 1,533 1,032 747 2,274
it Frequency
erbation of chronic obstructive pulmonary disease (AECOPD),
Table 1 Demographic and Comorbidities of Patients with Chronic Obstructive Pulmonary Disease (COPD), according to
the number of COPD-related emergency department visits in one year
1 ED visit 2 ED visits ≥ 3 ED visits
Variables* (n = 69,398) (n = 17,005) (n = 11,877) P value†
Age (y), median (IQR) 69 (58–79) 69 (59–78) 67 (58–76) <0.001‡
40-54 years 11,922 (17) 2595 (15) 2010 (17) <0.001
55-64 years 14,807 (21) 3815 (22) 3288 (28)
65-74 years 17,049 (25) 4575 (27) 3287 (28)
75-84 years 16,788 (24) 4160 (24) 2441 (21)
85 years and older 8832 (13) 1860 (11) 851 (7)
Male sex 30,633 (44) 7632 (45) 5527 (47) <0.001
Race/ethnicity <0.001
Non-hispanic white 51,557 (74) 12,746 (75) 8713 (73)
Non-hispanic black 6349 (9) 1702 (10) 1577 (13)
Hispanic 7715 (11) 1732 (10) 1068 (9)
Other 2484 (4) 569 (3) 337 (3)
Missing 1303 (2) 256 (2) 182 (2)
Insurance status
Medicare 46,174 (67) 11,829 (70) 7793 (66) <0.001
Medicaid 8092 (12) 2417 (14) 2413 (20)
Private 7931 (11) 1299 (8) 729 (6)
Self-pay 4322 (6) 71 (4) 431 (4)
Other 2870 (4) 699 (4) 508 (4)
Quartiles for median household income of patient’s ZIP code <0.001
1 (lowest) 22,390 (32) 5749 (34) 4415 (37)
2 19,307 (28) 4800 (28) 3325 (28)
3 15,904 (23) 3797 (22) 2497 (21)
4 (highest) 10,524 (15) 2308 (14) 1372 (12)
Missing 1273 (2) 351 (2) 268 (2)
Patient residence <0.001
Counties of≥ 1 million population 42,303 (61) 10,245 (60) 7123 (60)
Counties of 250,000-999,999 population 17,379 (25) 4319 (25) 2983 (25)
Counties of 50,000-249,999 population 4103 (6) 1053 (6) 750 (6)
Counties of < 50,000 population 5590 (8) 1335 (8) 956 (8)
State 0.02
California 33,741 (49) 8297 (49) 5942 (50)
Florida 35,657 (51) 8708 (51) 5935 (50)
Any comorbidities 54,633 (79) 13,888 (82) 9644 (81) <0.001
Selected comorbidities§
Congestive heart failure 13,607 (20) 3831 (23) 2708 (23) <0.001
Pulmonary circulation disorders 674 (1) 269 (2) 198 (2) <0.001
Diabetes, uncomplicated 14,813 (21) 3931 (23) 2939 (25) <0.001
Obesity 7195 (10) 1935 (11) 1437 (12) <0.001
Depression 6357 (9) 1886 (11) 1479 (12) <0.001
Psychoses 3233 (5) 1001 (6) 847 (7) <0.001
Drug abuse 1430 (2) 458 (3) 528 (4) <0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, IQR interquartile range.
*Data were expressed as n (%) unless otherwise indicated.
†Unadjusted comparisons were tested using chi-square test unless otherwise indicated.
‡Unadjusted comparison was tested using Kruskal-Wallis test.
§Comorbidity was defined as at least 1 Elixhauser comorbidity measure.
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Table 2 Multinomial regression models for factors associated with frequent emergency department visits for acute
exacerbation of chronic obstructive pulmonary disease
2 (vs. 1) ED visits ≥ 3 (vs. 1) ED visits
Variables Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age, y <0.001 <0.001
40-54 years 1 [reference] 1 [reference]
55-64 years 1.15 (1.09-1.22) <0.001 1.31 (1.23-1.39) <0.001
65-74 years 1.14 (1.07-1.22) <0.001 1.11 (1.03-1.20) 0.006
75-84 years 1.05 (0.98-1.12) 0.10 0.86 (0.79-0.93) <0.001
85 years and older 0.90 (0.83-0.97) 0.03 0.58 (0.52-0.64) <0.001
Male sex 1.04 (1.00-1.08) 0.048 1.12 (1.07-1.17) <0.001
Race/ethnicity
Non-hispanic white 1.15 (1.08-1.21) <0.001 1.32 (1.23-1.41) <0.001
Non-hispanic black 1.17 (1.09-1.27) <0.001 1.59 (1.46-1.73) <0.001
Hispanic 1 [reference] 1 [reference]
Other 1.07 (0.96-1.19) 0.29 1.07 (0.96-1.19) 0.33
Insurance status
Medicare 1.58 (1.47-1.69) <0.001 2.10 (1.92-2.29) <0.001
Medicaid 1.77 (1.64-1.92) <0.001 2.92 (2.66-3.20) <0.001
Private 1 [reference] 1 [reference]
Self-pay 1.11 (1.00-1.23) 0.046 1.05 (0.92-1.20) 0.45
Other 1.46 (1.32-1.62) <0.001 1.78 (1.57-2.02) <0.001
Quartiles for median household income of patient’s ZIP code
1 (lowest) 1.13 (1.07-1.20) <0.001 1.29 (1.21-1.38) <0.001
2 1.11 (1.05-1.18) <0.001 1.22 (1.14-1.31) <0.001
3 1.08 (1.01-1.14) 0.01 1.14 (1.06-1.22) <0.001
4 (highest) 1 [reference] 1 [reference]
Patient residence
Counties of ≥ 1 million population 1.07 (1.00-1.15) 0.06 1.09 (1.01-1.18) 0.03
Counties of 250,000-999,999 population 1.07 (1.00-1.15) 0.07 1.09 (1.00-1.18) 0.06
Counties of 50,000-249,999 population 1.09 (1.00-1.20) 0.06 1.10 (0.99-1.23) 0.09
Counties of < 50,000 population 1 [reference] 1 [reference]
State
California 1.01 (0.98-1.05) 0.44 1.06 (1.02-1.11) 0.006
Florida 1 [reference] 1 [reference]
Selected comorbidities*
Congestive heart failure 1.17 (1.11-1.22) <0.001 1.24 (1.17-1.30) <0.001
Pulmonary circulation disorders 1.41 (1.22-1.64) <0.001 1.39 (1.17-1.64) <0.001
Diabetes, uncomplicated 1.05 (1.01-1.10) 0.02 1.13 (1.07-1.19) <0.001
Obesity 0.99 (0.94-1.05) 0.79 0.97 (0.91-1.03) 0.31
Depression 1.21 (1.14-1.28) <0.001 1.38 (1.30-1.47) <0.001
Psychoses 1.17 (1.09-1.27) <0.001 1.27 (1.17-1.38) <0.001
Drug abuse 1.22 (1.09-1.37) <0.001 1.66 (1.48-1.85) <0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, CI confidence interval.
Bold results are statistically significant.
*Non-significant Elixhauser comorbidity measures across the frequency groups included peripheral vascular disease, hypertension, neurological disorders, diabetes
with complications, liver disease, peptic ulcer disease, acquired immunodeficiency syndrome, lymphoma, solid tumor without metastasis, coagulopathy, fluid and
electrolyte disorders, anemia, and alcohol abuse.
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Table 3 Multinomial regression models for factors associated with frequent emergency department visits for acute
exacerbation of chronic obstructive pulmonary disease, stratified by state
California Florida
2 (vs. 1) ED visits ≥ 3 (vs. 1) ED visits 2 (vs. 1) ED visits ≥ 3 (vs. 1) ED visits
Variables Odds ratio
(95% CI)
P
value
Odds ratio
(95% CI)
P
value
Odds ratio
(95% CI)
P
value
Odds ratio
(95% CI)
P
value
Age, y
40-54 years 1 [reference] 1 [reference] 1 [reference] 1 [reference]
55-64 years 1.20 (1.11-1.31) <0.001 1.32 (1.21-1.45) <0.001 1.11 (1.03-1.21) 0.008 1.28 (1.17-1.41) <0.001
65-74 years 1.17 (1.07-1.29) 0.001 1.16 (1.04-1.29) 0.008 1.13 (1.03-1.23) 0.01 1.05 (0.95-1.17) 0.34
75-84 years 1.15 (1.04-1.27) 0.007 0.90 (0.80-1.01) 0.08 0.98 (0.89-1.08) 0.73 1.81 (0.73-0.91) <0.001
85 years and older 0.99 (0.88-1.11) 0.83 0.61 (0.53-0.70) <0.001 0.85 (0.76-0.96) 0.007 0.54 (0.47-0.63) <0.001
Male sex 1.05 (1.00-1.10) 0.048 1.13 (1.06-1.19) <0.001 1.03 (0.98-1.08) 0.30 1.11 (1.05-1.18) <0.001
Race/ethnicity
Non-hispanic white 1.15 (1.06-1.25) 0.001 1.32 (1.20-1.46) <0.001 1.13 (1.03-1.23) 0.004 1.30 (1.17-1.44) <0.001
Non-hispanic black 1.24 (1.11-1.38) 0.001 1.71 (1.51-1.93) <0.001 1.12 (1.01-1.25) 0.04 1.49 (1.31-1.69) <0.001
Hispanic 1 [reference] 1 [reference] 1 [reference] 1 [reference]
Other 1.23 (1.00-1.28) 0.06 1.16 (0.99-1.35) 0.06 0.85 (0.65-1.10) 0.21 0.80 (0.57-1.12) 0.20
Insurance status
Medicare 1.55 (1.41-1.71) <0.001 1.88 (1.67-2.11) <0.001 1.63 (1.47-1.81) <0.001 2.41 (2.11-2.75) <0.001
Medicaid 1.65 (1.48-1.83) <0.001 2.58 (2.29-2.92) <0.001 1.96 (1.75-2.20) <0.001 3.38 (2.93-3.89) <0.001
Private 1 [reference] 1 [reference] 1 [reference] 1 [reference]
Self-pay 1.10 (0.95-1.28) 0.21 1.05 (0.87-1.27) 0.62 1.13 (0.98-1.29) 0.09 1.11 (0.92-1.33) 0.29
Other 1.34 (1.14-1.57) <0.001 1.34 (1.10-1.62) 0.004 1.58 (1.37-1.81) <0.001 2.25 (1.90-2.67) <0.001
Quartiles for median household
income of patient’s ZIP code
1 (lowest) 1.24 (1.13-1.37) <0.001 1.18 (1.09-1.28) <0.001 1.10 (1.01-1.19) 0.03 1.22 (1.11-1.34) <0.001
2 1.22 (1.12-1.32) <0.001 1.24 (1.13-1.37) <0.001 1.03 (0.95-1.11) 0.49 1.19 (1.08-1.31) <0.001
3 1.12 (1.03-1.21) 0.001 1.20 (1.09-1.33) <0.001 1.04 (0.95-1.13) 0.40 1.07 (0.97-1.19) 0.19
4 (highest) 1 [reference] 1 [reference] 1 [reference] 1 [reference]
Patient residence
Counties of ≥ 1 million population 1.00 (0.89-1.12) 0.99 0.97 (0.86-1.11) 0.69 1.10 (1.01-1.20) 0.03 1.16 (1.04-1.28) 0.005
Counties of 250,000-999,999
population
1.06 (0.94-1.20) 0.34 1.02 (0.89-1.17) 0.78 1.07 (0.98-1.17) 0.16 1.09 (0.98-1.22) 0.10
Counties of 50,000-249,999
population
1.01 (0.87-1.06) 0.92 1.04 (0.89-1.22) 0.65 1.16 (1.02-1.32) 0.02 1.10 (0.94-1.28) 0.23
Counties of < 50,000 population 1 [reference] 1 [reference] 1 [reference] 1 [reference]
Selected comorbidities
Congestive heart failure 1.16 (1.09-1.23) <0.001 1.27 (1.18-1.36) <0.001 1.18 (1.11-1.26) <0.001 1.22 (1.13-1.31) <0.001
Pulmonary circulation disorders 1.51 (1.22-1.86) <0.001 1.34 (1.04-1.73) 0.02 1.29 (1.05-1.60) 0.02 1.37 (1.09-1.73) 0.008
Diabetes, uncomplicated 1.02 (0.96-1.09) 0.47 1.14 (1.06-1.23) <0.001 1.08 (1.02-1.15) 0.009 1.12 (1.05-1.20) <0.001
Obesity 1.01 (0.92-1.10) 0.85 0.96 (0.87-1.06) 0.42 0.98 (0.91-1.06) 0.60 0.97 (0.89-1.06) 0.50
Depression 1.22 (1.11-1.33) <0.001 1.39 (1.26-1.54) <0.001 1.19 (1.10-1.28) <0.001 1.37 (1.26-1.49) <0.001
Psychoses 1.19 (1.07-1.32) 0.001 1.26 (1.13-1.42) <0.001 1.16 (1.04-1.29) 0.01 1.28 (1.14-1.45) <0.001
Drug abuse 1.27 (1.10-1.47) 0.001 1.72 (1.49-1.97) <0.001 1.16 (0.97-1.39) 0.10 1.55 (1.30-1.86) <0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, CI confidence interval.
Bold results are statistically significant.
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Table 4 Negative binomial regression model for factors associated with frequency of emergency department visits for
acute exacerbation of chronic obstructive pulmonary disease
Variables Risk ratio (95% CI) P value
Age, y
40-54 years 1 [reference]
55-64 years 1.07 (1.06-1.09) <0.001
65-74 years 1.02 (1.00-1.03) 0.04
75-84 years 0.94 (0.92-0.96) <0.001
85 years and older 0.86 (0.85-0.88) <0.001
Male sex
Race/ethnicity
Non-hispanic white 1.08 (1.06-1.09) <0.001
Non-hispanic black 1.15 (1.13-1.17) <0.001
Hispanic 1 [reference]
Other 1.01 (0.98-1.03) 0.62
Insurance status
Medicare 1.21 (1.19-1.23) <0.001
Medicaid 1.34 (1.32-1.36) <0.001
Private 1 [reference]
Self-pay 1.01 (0.99-1.03) 0.45
Other 1.13 (1.10-1.16) <0.001
Quartiles for median household income of patient’s ZIP code
1 (lowest) 1.06 (1.05-1.08) <0.001
2 1.05 (1.03-1.06) <0.001
3 1.03 (1.01-1.04) <0.001
4 (highest) 1 [reference]
Patient residence
Counties of ≥ 1 million population 1.03 (1.01-1.05) <0.001
Counties of 250,000-999,999 population 1.04 (1.02-1.05) <0.001
Counties of 50,000-249,999 population 1.03 (1.01-1.06) 0.007
Counties of < 50,000 population 1 [reference]
State
California 1.02 (1.02-1.03) <0.001
Florida 1 [reference]
Selected comorbidities
Congestive heart failure 1.05 (1.04-1.06) <0.001
Pulmonary circulation disorders 1.13 (1.09-1.17) <0.001
Diabetes, uncomplicated 1.04 (1.03-1.05) <0.001
Obesity 0.97 (0.96-0.99) <0.001
Depression 1.08 (1.07-1.10) <0.001
Psychoses 1.08 (1.06-1.10) <0.001
Drug abuse 1.18 (1.15-1.21) <0.001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department CI confidence interval.
Bold results are statistically significant.
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Table 5 Outcomes of patients with Chronic Obstructive Pulmonary Disease (COPD), according to the number of COPD-
related emergency department visits in one year
Variables 1 ED visit 2 ED visits ≥ 3 ED visits P value
Number of ED visits for COPD, no. 69,398 34,010 51,328 –
30-day ED revisit rate for COPD, % (95% CI)* – 10.5 (10.1-10.8) 30.0 (29.6-30.4) <0.001
Hospitalization rate for COPD, % (95% CI) 62.3 (62.0-62.7) 64.9 (64.4-65.4) 62.1 (61.6-62.5) <0.001
Near-fatal event rate, % (95% CI) 5.8 (5.6-6.0) 8.2 (7.9-8.5) 8.8 (8.6-9.1) <0.001
Abbreviations: COPD chronic obstructive pulmonary disease ED emergency department, IQR interquartile range, CI confidence interval.
*Excluding the index ED visits and hospitalizations.
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events
Table 5 summarizes clinical outcomes at the visit-level.
Overall, 12.3% (95% CI, 12.1%-12.4%) of ED visits for
AECOPD were 30-day revisit events. Patients with a
higher frequency of ED visits were more likely to de-
velop a 30-day ED revisit (Table 5), regardless of state
(all P < 0.001; Table 6).
Overall, approximately two-thirds of ED visits (62.8%;
95% CI, 62.6%-63.0%) resulted in a hospitalization.
Hospitalization rates were greater than 60% across the
ED frequency groups and highest with the patients
with two ED visits (Table 5). Patients with frequent ED
visits accounted for 55.5% (95% CI, 55.2%-55.8%) of
total hospitalizations for AECOPD.
Additionally, 7.3% (95% CI, 7.2%-7.5%) of ED visits
led to a near-fatal event. Patients with a higher frequency
of ED visits had a higher chance of near-fatal event during
the 1-year period, regardless of state (all P < 0.001; Tables 5
and 6). Patients with frequent ED visits accounted for
64.4% (95% CI, 63.5%-65.3%) of near-fatal events.Table 6 Outcomes of chronic obstructive pulmonary disease p
department visits, stratified by state
Variables 1 ED visit
California
Number of ED visits for COPD, no. 33,741
30-day ED revisit rate for COPD, % (95% CI)* –
Hospitalization rate for COPD, % (95% CI) 55.7 (55.2-56.2)
Near-fatal event rate, % (95% CI) 6.8 (6.5-7.1)
Florida
Number of ED visits for COPD, no. 35,657
30-day ED revisit rate for COPD, % (95% CI)* –
Hospitalization rate for COPD, % (95% CI) 68.6 (68.1-69.0)
Near-fatal event rate, % (95% CI) 4.9 (4.7-5.1)
Nebraska
Number of ED visits for COPD, no. 2009
30-day ED revisit rate for COPD, % (95% CI)* –
Hospitalization rate for COPD, % (95% CI) 52.5 (50.3-54.7)
Near-fatal event rate, % (95% CI) 6.9 (5.8-8.1)
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency departm
*Excluding the index ED visits and hospitalizations.Hospital charges for AECOPD in Florida
The total charges for ED and inpatient services for
AECOPD were $1.94 billion (95% CI, $1.90-1.97 billion)
in Florida. Patients with frequent ED visits accounted
for the majority of total charges ($1.07 billion; 95% CI,
$1.04-1.09 billion); this was driven by a significant linear
association between number of ED visits and charges
per patient (P < 0.001; Figure 3). In addition, recurrent
visits after the index ED visits accounted for 37.1% of
total charges ($719 million; 95% CI, $709-731 million).
Discussion
Our study of 98,280 COPD patients showed that 29% of
the patients had frequent ED visits for AECOPD (2 or
more ED visits in a year). The societal burden of this
population with COPD – as measured by ED visits,
hospitalizations, and near-fatal events – was large. In-
deed, this high-risk population accounted for 55% of all
ED visits, 56% of all COPD hospitalizations, 64% of
near-fatal events, all contributing to substantial healthcare
spending. We also found that male sex, non-Hispanicatients, according to the number of emergency
2 ED visits ≥ 3 ED visits P value
16,594 26,100 –
11.1 (10.6-11.6) 31.7 (31.2-32.3) <0.001
54.6 (53.9-55.4) 54.5 (53.9-55.1) <0.001
9.2 (8.7-9.6) 9.6 (9.2-9.9) <0.001
17,416 25,228 –
9.8 (9.4-10.3) 28.2 (27.6-28.8) <0.001
71.7 (71.0-72.3) 69.9 (69.3-70.4) <0.001
7.3 (6.9-7.7) 9.9 (9.5-10.3) <0.001
1060 1301
8.6 (7.0-10.4) 27.2 (24.8-29.7) <0.001
56.6 (53.6-59.6) 53.0 (50.2-55.7) 0.08
7.9 (6.4-9.7) 11.2 (9.6-13.1) <0.001
ent, IQR interquartile range CI confidence interval.
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Figure 3 Median and cumulative charges for emergency department (ED) and inpatient services for acute exacerbation of chronic
obstructive pulmonary disease (AECOPD), according to ED visit frequency. There was a significant linear association between frequency of
ED visits and charges per patient (P < 0.001).
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were significantly associated with a higher frequency of
ED visits. These findings inform potential strategies to re-
duce the large public health burden from AECOPD.
Proportion of frequent ED visits for AECOPD
To date, most clinical research on patients with AECOPD
has focused on predicting and preventing acute relapse
and 30-day readmission [22-24]. However, the predictors
of acute relapse are not necessarily the predictors of
frequent ED visits over longer periods. Conceptually,
relapse is more likely to be associated with acute or
medical factors, such as severity of exacerbation and
quality of care at the index ED visit or hospitalization
[24]. In contrast to acute relapse, recurrent ED visits for
AECOPD over the course of a longer period of time,
such as 1 year in our study, have a broader meaning
because it may reflect a failure of less costly and more
prevention-oriented COPD care.
A multicenter ED-based study in the early 2000s
found that 64% of ED patients with AECOPD self-
reported frequent ED visits within past year [11]. By
contrast, a claims data study from North Carolina found
that 28% of ED patients with AECOPD had frequent ED
visits in the late 2000s [10]. Between 2010 and 2011, we
demonstrated that 29% of ED patients with AECOPD
had frequent ED visits in the two large, geographically-
dispersed states, with a comparable percentage in a
third state.
The reasons for the differences in the proportion of
frequent ED visits for AECOPD among the studies are
unclear and likely multifactorial. The population of the
earlier multicenter study was limited to urban teaching
hospitals that might have disproportionately high COPDmorbidity, and thereby led to more frequent ED visits.
Alternatively, the observed lower proportion of fre-
quent ED visits might reflect declines in the rate of
severe AECOPD over the past decade [1,25]. Secular
changes in multiple factors might have contributed
to such a potential improvement, including favorable
changes in personal health behavior (e.g., smoking),
self-management education, access to longitudinal care,
hospital-at-home care, and dissemination of evidence-
based therapy. For example, the release of Global Initia-
tives for Chronic Obstructive Lung Disease guidelines
in 2001, 2006, and 2011 may have helped reduce the
rate of AECOPD [26]. Indeed, after the publication of
the first guidelines, researchers reported increases in
the use of long-acting beta-agonists with corticosteroids
[27] and influenza vaccinations [28] as well as reduc-
tions in smoking rate [29]. However, although COPD
care has improved, the use of recommended medication
combinations and stage-appropriate treatment still has
ample room for improvement [30]. The observed lower
proportion of frequent ED visits for AECOPD in 2010–
2011 supports cautious optimism that COPD morbid-
ity can be prevented and the societal burden reduced.
Yet, considering the previous knowledge that only half of
patients with AECOPD seek care in the ED or outpatient
clinics [31], the large remaining burden underscores the
need for continued secondary prevention efforts among
patients with COPD.
Characteristics of patients with frequent ED visits for
AECOPD
We were also struck by the disproportionate socioeco-
nomic disparity in frequency of ED visits for AECOPD.
In the present study, we found that adults at highest
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lic insurance, and to have lower socioeconomic status.
These results support prior reports of higher rates of
frequent ED visits for COPD among these vulnerable
populations [10,11]. Although the precise role of lower
socioeconomic status to this disparity in COPD health-
care utilizations is unclear [5], the asthma literature
would suggest that differences in health beliefs, less
self-management education, and limited access to pre-
ventive and specialist care in this population might lead
to a heavier reliance on episodic symptom treatment
and emergency care [32]. Other potential factors that
might explain the difference in ED use across socio-
economic status include degree of past and current
smoking, living conditions, outpatient treatment, and
COPD-specific disease severity [5,33]. The pathway
through which socioeconomic status affects healthcare
utilization is undoubtedly complex; further investiga-
tion is warranted to better understand the underlying
reasons for this disparity in ED utilization among pa-
tients with AECOPD.
Burden of patients with frequent ED visits for AECOPD
Consistent with the previous study from North Carolina
[10], we observed substantial patient morbidity, as mea-
sured by ED visits and hospitalizations for AECOPD.
Additionally, our study extended prior research by
documenting relatively high use of intensive care re-
sources and high healthcare spending in frequent ED
users with AECOPD. Indeed, patients with frequent ED
visits accounted for only 29% of all patients; however,
they comprised 64% of mechanical ventilation use and
55% of the total charges for ED and inpatient services.
COPD is designated as an ambulatory care sensitive
condition by the AHRQ, among other conditions [34]; ED
visits for AECOPD can often be prevented by evidence-
based outpatient care (e.g., smoking cessation, influenza
and pneumococcal vaccines, knowledge of current therapy
including inhaler technique, and evidence-based pharma-
cologic treatment) [5]. Therefore, organized efforts to de-
velop and implement systems of care are imperative to
lower COPD adverse outcomes and healthcare expendi-
tures. If recurrent ED visits could be prevented in this
study, there would have been approximately 56,456 pre-
vented ED visits and 35,520 prevented hospitalizations in
these two states alone. In terms of cost, this would have
saved 719 million dollars in Florida alone.
Although these administrative data are unable to
explore more granular aspects of COPD care, our find-
ings can better inform a system of care for patients with
AECOPD. At the individual patient level, the use of
patient characteristics to identify patients at high-risk for
frequent AECOPD remains limited [35]. The present find-
ings underscore the importance of translating high-qualityresearch into the risk stratification, coupled with dissemin-
ation of these finding to improve care for patients with
COPD. At the health system level, our observation should
facilitate further work on how to reduce the enormous
and uneven public heath burden by targeting the popula-
tion at greatest risk for integrated research, health policy,
and community action.
Potential limitations
Our study should be viewed in the context of several po-
tential limitations. Our data were not derived from a
sample of the national COPD population. However, the
data from two geographically diverse states included all
ED visits and hospitalizations for approximately 19% of
the US population [36]; the age and sex distributions of
the ED visits mirrored a national surveillance of COPD-
related ED visits [1]. Moreover, our findings persisted
across the two geographically dispersed states, with the
comparable findings in a third state, suggesting a poten-
tial generalizability at the nation-level. Secondly, as with
any studies using administrative data, there may be some
misclassification of medical claims. However, HCUP data
are highly accurate, rigorously tested, and widely used to
estimate diagnoses and visit frequency [37,38]. Thirdly,
our data do not include information on outpatient treat-
ment and COPD-specific disease severity measures. As
a surrogate for severity for COPD, we controlled for
Elixhauser comorbidity measures in our analysis. In
addition, our study did not examine care coordination,
such as early discharge to pulmonary rehabilitation, or
nurse or self-management education [39,40]. Fourthly,
some of the unadjusted comparisons of patient charac-
teristics were statistically significant with a marginal
clinical significance because of the large numbers. Lastly,
our objective was to assess COPD-related ED visits and
associated healthcare utilization. Some patients may
have had visits to urgent care or other ambulatory care
sites; this would have led to an underestimation of
healthcare utilization for AECOPD. However, because
we focused on the characteristics and burden of the
frequent ED utilizers for COPD, our observations are
of direct relevance to the development of strategies to
improve COPD care in this important patient population.
Conclusions
By using large all-payer databases from two geographic-
ally dispersed states in US, we found that 29% of the ED
patients with AECOPD had frequent ED visits and that
lower socioeconomic status were significantly associated
with a higher frequency of ED visits. This population
accounts for the majority of all COPD-related ED visits,
hospitalizations, near-fatal events, and hospital charges,
and present an important public health challenge. Our
observations provide a strong foundation for clinicians
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(e.g., frequent ED users) and to develop targeted pre-
ventive interventions. For policy makers, our findings
underscore the importance of integrated strategies aimed
at reducing COPD-related healthcare utilizations in an
already-stressed healthcare system.
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